NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2024 and Provides Business Updates

Core Insights - NeuroPace, Inc. announced preliminary unaudited revenue expectations for Q4 2024 between $21.0 million and$21.5 million, and for the full year 2024 between $79.4 million and$79.9 million, indicating growth of 17% to 19% for Q4 and 21% to 22% for the full year compared to 2023 [1][8] Financial Performance - The company achieved over 20% revenue growth in 2024, with strong gross margin performance and reduced cash burn while investing in long-term growth [4] - Cash and short-term investments as of December 31, 2024, are expected to be $52.8 million, with total shares of common stock outstanding anticipated to be 30,145,039 [8] Management and Board Updates - Scott Huennekens was appointed to the Board of Directors effective January 6, 2025, bringing extensive management and investment experience in the medtech sector [5][6] - Huennekens has a successful track record with over 20 medical device companies, contributing to significant shareholder value [7] Upcoming Events - The company will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025, and will host an Investor Day on January 28, 2025, in New York City [14]